Plectin’s ability to promote cell proliferation and invasion was previously demonstrated in pancreatic ductal adenocarcinoma, non-small-cell lung cancer, high-grade epithelial ovarian cancer, prostate cancer, and head and neck squamous cell carcinoma [20]. Here, PLEC is linked to prostate cancer.